Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $4.2 million.

  • Beam Therapeutics' Amortizatization of Intangibles fell 2471.99% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year decrease of 3194.4%. This contributed to the annual value of $22.8 million for FY2024, which is 2346.1% down from last year.
  • Latest data reveals that Beam Therapeutics reported Amortizatization of Intangibles of $4.2 million as of Q3 2025, which was down 2471.99% from $4.6 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Amortizatization of Intangibles high stood at $7.9 million for Q3 2023, and its period low was -$15000.0 during Q1 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $4.6 million (2025), whereas its average is $3.9 million.
  • As far as peak fluctuations go, Beam Therapeutics' Amortizatization of Intangibles tumbled by 11162.79% in 2021, and later soared by 1276800.0% in 2022.
  • Beam Therapeutics' Amortizatization of Intangibles (Quarter) stood at $47000.0 in 2021, then skyrocketed by 10755.32% to $5.1 million in 2022, then surged by 44.14% to $7.4 million in 2023, then plummeted by 36.91% to $4.6 million in 2024, then dropped by 8.77% to $4.2 million in 2025.
  • Its Amortizatization of Intangibles was $4.2 million in Q3 2025, compared to $4.6 million in Q2 2025 and $3.8 million in Q1 2025.